Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform

Go back to Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform

Leerink Partners Raises Price Target on Regeneron (REGN) Following 1Q Report

May 6, 2016 9:08 AM EDT

Leerink Partners reiterated an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and raised the price target to $530.00 (from $523.00), following the company's 1Q earnings report. Total revenue beat consensus by 2% driven by higher collaboration revenue, and revenue grew by 38% compared to Q1 2015 and by 9% QoQ. The companys earnings fell short of consensus based on higher than expected SG&A and taxes. Pro forma EPS was $2.57 below consensus of $2.68.

Analyst Geoffrey Porges... More

Regeneron (REGN) Misses Q1 EPS by 1c; Reaffirms

May 5, 2016 6:36 AM EDT

Regeneron (NASDAQ: REGN) reported Q1 EPS of $2.57, $0.01 worse than the analyst estimate of $2.58. Revenue for the quarter came in at $1.2 billion versus the consensus estimate of $1.18 billion.

"The year is off to a very productive start at Regeneron. This quarter, we saw continued strong sales growth with EYLEA, made additional... More

Trading Radar for 5/5: Alibaba (BABA), GoPro (GPRO), Herbalife (HLF), Wynn Resorts (WYNN), Activision (ATVI) Report

May 4, 2016 2:39 PM EDT

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:
Economics:
8:30am EDT

Initial Claims - Street sees 259k

Earnings:

3D Systems (NYSE: DDD) - consensus EPS $0.05
AAC Holdings (NYSE: AAC) - consensus EPS $0.15
ACI Worldwide, Inc. (Nasdaq: ACIW) - consensus loss $0.08
Agios Pharma (Nasdaq: AGIO) - consensus loss $0.79
Alibaba (NYSE: BABA) - consensus EPS... More

Sanofi sees 'strong strategic' fit with U.S. Medivation

May 4, 2016 10:39 AM EDT

PARIS (Reuters) - Sanofi sees a strong strategic fit with Medivation (NASDAQ: MDVN) even though its tie-up proposal was rejected by the U.S. cancer drug maker last week, the company's chief executive said on Wednesday.

The French drugmaker went public with a $9.3 billion proposal to buy Medivation on April 28 but the target said offer undervalued the company and its pipeline of drugs.

... More

Big pharma dominates ranking of stocks with best five-year returns

May 3, 2016 10:24 AM EDT

By Laila Kearney

NEW YORK (Reuters) - U.S. pharmaceutical companies dominated an annual global ranking of top 10 large-cap stocks with the best five-year returns, according to an analysis released on Tuesday by Boston Consulting Group.

Drug company Regeneron Pharmaceuticals (NASDAQ: REGN), which had an average annual total share return of 75.3 percent, was the top performer. Allergan (NYSE: AGN) and Gilead Sciences (NASDAQ: GILD), with 43.3 percent and 41.4 percent average annual returns, respectively, took second and third... More